CN110327373B - Application of maggot wine-soaked product in treatment of diabetes - Google Patents
Application of maggot wine-soaked product in treatment of diabetes Download PDFInfo
- Publication number
- CN110327373B CN110327373B CN201910642598.7A CN201910642598A CN110327373B CN 110327373 B CN110327373 B CN 110327373B CN 201910642598 A CN201910642598 A CN 201910642598A CN 110327373 B CN110327373 B CN 110327373B
- Authority
- CN
- China
- Prior art keywords
- maggot
- wine
- maggots
- whole
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title abstract description 40
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 62
- 238000002791 soaking Methods 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 102000004877 Insulin Human genes 0.000 claims abstract description 31
- 108090001061 Insulin Proteins 0.000 claims abstract description 31
- 229940125396 insulin Drugs 0.000 claims abstract description 31
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 238000004659 sterilization and disinfection Methods 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 9
- 230000000249 desinfective effect Effects 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 29
- 210000004369 blood Anatomy 0.000 abstract description 29
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 25
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 238000012795 verification Methods 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 2
- 230000003914 insulin secretion Effects 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 241000722809 Armadillidium vulgare Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000202815 Chrysomya megacephala Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000501743 Gentiana macrophylla Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241000920471 Lucilia caesar Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an application of a maggot wine soaking product in treating diabetes, wherein the maggot wine soaking product is used for preparing a composition for treating the diabetes or preparing a composition for regulating insulin level. The research shows that the maggots, especially the maggot wine soaking products can effectively eliminate and reverse human insulin resistance and improve human insulin sensitivity, the maggot wine soaking products can obviously reverse blood sugar level to be normal after the maggots wine soaking products are taken by patients for treatment in effect verification, and blood sugar is stable for a long time after all medicines are stopped for treatment. Is the first significant discovery of Chinese traditional medicine for treating diabetes.
Description
Technical Field
The invention belongs to the technical field of food and medicine, and particularly relates to an application of a maggot wine-soaking product in treatment of diabetes.
Background
Insulin is a protein-like hormone, and insulin in vivo is secreted by pancreatic islet beta cells.
Islet cells are classified into the following according to their hormone-secreting function:
the B cell (beta cell) accounts for about 60-80% of the islet cell, secretes insulin, and the insulin can reduce blood sugar.
② A cells (alpha cells) which account for about 24-40% of islet cells, secretes glucagon, the action of glucagon is opposite to that of insulin, and can increase blood sugar.
③ D cells, accounting for about 6 to 15 percent of the total number of the islet cells, secrete growth hormone inhibitory hormone.
The pathophysiology of diabetes patients is mainly caused by relative or absolute deficiency of insulin activity and relative or absolute excess of glucagon activity, namely B and A cell bilateral hormone dysfunction, due to various pathogenic factors such as virus infection, genetic genes, autoimmunity and the like. Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by a defect in insulin secretion or an impaired biological action, or both. Hyperglycemia occurring in long-term diabetes causes chronic damage to various tissues, particularly eyes, kidneys, heart, blood vessels, nerves, dysfunction, and the like. At present, no method is available all over the world for recovering and reversing the function of insulin in a human body in the process of treating diabetes.
The maggot is dry larva of Chrysomyia megacephala or other kindred insects of the family of blowfly, the Chinese medicinal maggot is named as maggot, Narcissus tazetta and Luoxian seed, the maggot is salty, sweet and cold in nature, passes through spleen and stomach, mainly contains protein, lysozyme, amino acid and grease in chemical components, has low toxicity, and has the effects of clearing heat and removing toxicity, and removing food retention and removing food stagnation. It is recorded in Ben Cao gang mu (compendium of materia Medica) for treating infantile malnutrition, fever and delirium, dysentery with toxic pathogen and vomiting. Therefore, the effective components in the maggot not only have the functions of resisting bacteria and viruses, but also have the functions of resisting parasites, oxidation, aging, tumors and the like.
In the prior art, patent CN107375825A discloses a medicine for treating diabetes, which is prepared from dietary alkali, pillbug, ant, maggot, mulberry leaf, trichosanthes root, gypsum, radix rehmanniae, prepared rehmannia root, medlar, mulberry, gentiana macrophylla, red ginseng, American ginseng, kudzu vine root and the like according to a certain weight ratio. The maggot adopted by the composition has the effects of clearing heat and eliminating stagnation, and is a ministerial drug.
Patent CN102335241A describes a medicine for treating diabetes complicated with hyperlipidemia, which is prepared from the following raw material medicines in parts by weight: 6-10 parts of raw rhubarb, 3-10 parts of leech, 10-30 parts of maggot, 10-30 parts of red yeast rice and 10-15 parts of schisandra chinensis. It has long-lasting and high curative effect. The maggot adopted by the composition is also added by utilizing the salty cold of the maggot entering spleen and stomach channels, eliminating stagnation, clearing heat and obviously reducing the lipid.
Patent CN108404088A describes a medicine for treating type II diabetes, which is prepared from the following raw materials in parts by weight: 30-80 parts of dried ginger, 150-220 parts of coptis chinensis, 150-220 parts of scutellaria baicalensis, 20-45 parts of American ginseng, 150-220 parts of trichosanthes kirilowii and 150-220 parts of maggot. The traditional Chinese medicine is used for treating symptoms such as thirst, fatigue, qi deficiency and no speaking caused by deficiency of both qi and yin through the traditional Chinese medicine treatment principle of clearing heat, lowering turbid pathogen, tonifying qi and nourishing yin, and is particularly suitable for treating type II diabetes with symptoms such as thirst, fatigue, no speaking and no speaking caused by deficiency of both qi and yin.
It can be seen that although the three patents only contain the maggots, the maggots have the effect of clearing heat and removing food stagnation, and the action of the maggots alone for treating diabetes, recovering insulin resistance and improving insulin sensitivity is not described.
Furthermore, all of the presently disclosed drugs (including the latest oral drugs) or methods for treating diabetes are not directly aimed at improving insulin resistance and insulin sensitivity, but at improving blood glucose.
Disclosure of Invention
The invention aims to provide an application of a maggot wine soaking product in treating diabetes, in particular to an application of the maggot wine soaking product in preparing a composition for treating the diabetes or a composition for regulating insulin level.
The purpose of the invention is realized by the following technical scheme:
in a first aspect, the present invention provides the use of a maggot extract product for the preparation of a composition for the treatment of diabetes.
In a second aspect, the present invention provides the use of a maggot extract product for the preparation of a composition for regulating insulin levels.
Preferably, the composition comprises any one of a pharmaceutical product, a nutraceutical product, a food product.
Preferably, the preparation method of the maggot wine-soaking product comprises the following steps:
b1, cleaning and washing the collected whole maggots to remove dirt on the surface;
b2, soaking and disinfecting the whole maggots treated in the step B1, washing and draining;
b3, putting the drained whole maggots into the wine, and sealing and storing;
and B4, taking out the whole maggots after being sealed and stored, and carrying out low-temperature ultrafine grinding to obtain the maggot feed additive.
Preferably, in the step B2, the disinfection solution used for the soaking disinfection is a mixture of water and peroxyacetic acid disinfection stock solution; more preferably, the soaking time is 10 minutes, and the volume ratio of water to the peroxyacetic acid disinfection stock solution is 1: 400.
Preferably, in the step B3, the ratio of the whole maggot to the wine in parts by weight is: 0.2: 0.8-0.4: 0.6; the sealing time is more than 2 months.
Preferably, the wine is pure grain wine with the alcoholic strength of 55-70 degrees.
Preferably, the formulation prepared from the maggot comprises any one of capsules, tablets, pills, powder, compound granules, health-care wine, oral liquid or freeze-dried powder.
In a third aspect, the present invention also provides a method for treating diabetes based on the aforementioned composition, comprising the steps of:
after detection, treatment is carried out for 1-6 courses of treatment according to the degree of the diabetes, and each course of treatment is three months; the treatment method of each course of treatment comprises the following steps: taking composition containing the maggot soaking product, wherein the dosage of the maggot soaking product in the composition taken every day is 1500mg-15 g.
In a fourth aspect, the present invention also provides a method for regulating insulin levels based on the aforementioned composition, comprising the steps of:
after detection, treatment is carried out for 1-6 courses of treatment according to the degree of the diabetes, and each course of treatment is three months; the treatment method of each course of treatment comprises the following steps: taking composition containing the maggot soaking product, wherein the dosage of the maggot soaking product in the composition taken every day is 1500mg-15 g.
Compared with the prior art, the invention has the following beneficial effects:
the maggot wine-soaking product of the invention is a natural product, the effective component of the maggot wine-soaking product is maggot whole worm, and the modern medical research proves that: the maggot contains protein, fat, chitosan, antibacterial peptide and amino acids. The maggot freeze-dried powder comprises all effective components of the whole maggot, and the maggot extract mainly comprises fatty acid and/or protein, polypeptide, amino acid and the like. The research shows that the maggot wine soaking product can effectively eliminate insulin resistance of a human body and improve insulin sensitivity of the human body, the fact that the insulin resistance of a diabetic patient can be obviously eliminated and the insulin level of part of the insulin sensitive patient can be greatly improved to be recovered to the level of normal people after the patient takes the maggot wine soaking product for treatment is found in effect verification, and the maggot wine soaking product does not have the drug resistance and the toxic and side effects of chemotherapy drugs commonly used clinically.
The inventor deeply researches the group suitable for treating diabetes by using the maggot soaking wine product, finds and finds evidence to prove that a human body has curative effects on insulin resistance and insulin sensitivity after taking the maggot soaking wine product through the measurement and comparison of front and back glucose tolerance (OGTT), and the blood sugar is stable for a long time after stopping all medicaments. Is the first significant discovery of Chinese traditional medicine for treating diabetes.
The maggot product is prepared into the medicine, the medicine is convenient to carry and take, the clinical effective rate reaches 98%, the patient can stay on the medicine after conventional treatment for more than five years, the state of illness is stable at present, and the blood sugar is normal.
Drawings
Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:
FIG. 1 is a sugar tolerance curve of the first example of the present invention;
FIG. 2 is a graph of insulin release curves according to a first embodiment of the present invention;
FIG. 3 is a sugar tolerance curve of a second inventive example;
FIG. 4 is an insulin release profile of a second example of the invention;
FIG. 5 shows the insulin release profile of a third example of the invention;
FIG. 6 is a sugar tolerance curve of a fourth inventive verification example;
FIG. 7 is an insulin release profile of a fourth example of the invention.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
The following example provides the use of a maggot extract product for the preparation of a composition for the treatment of diabetes.
The following example provides the use of a maggot extract product for preparing a composition for regulating insulin levels.
The composition comprises any one of medicines, health products and foods.
The preparation method of the maggot wine-soaking product comprises the following steps:
b1, cleaning and washing the collected whole maggots to remove dirt on the surface;
b2, soaking and disinfecting the whole maggots treated in the step B1, washing and draining;
b3, putting the drained whole maggots into the wine, and sealing and storing;
and B4, taking out the whole maggots after being sealed and stored, and carrying out low-temperature ultrafine grinding to obtain the maggot feed additive.
In the step B2, the disinfection solution adopted by the soaking disinfection is a mixture of water and peroxyacetic acid disinfection stock solution, and the soaking time is 10 minutes; more preferably, the volume ratio of water to peroxyacetic acid disinfection stock solution is 1: 400.
In the step B3, the weight parts of the whole maggot and the wine are as follows: 0.2: 0.8-0.4: 0.6; the sealing time is more than 2 months.
The wine is pure grain wine with the alcoholic strength of 55-70 degrees.
The formulation of the maggot soaking product comprises any one of capsules, tablets, pills, powder, compound granules, health care wine, oral liquid or freeze-dried powder.
The following embodiments also provide a method of regulating insulin levels in the treatment of diabetes based on the foregoing composition, comprising the steps of:
after detection, treatment is carried out for 1-6 courses of treatment according to the degree of the diabetes, and each course of treatment is three months; the treatment method of each course of treatment comprises the following steps: taking composition containing the maggot soaking product, wherein the dosage of the maggot soaking product in the composition taken every day is 1500mg-15 g.
Example 1
The embodiment provides a method for preparing maggot dry powder, which comprises the following steps:
a1, cleaning and washing the collected whole maggots to remove dirt on the surface;
a2, soaking and disinfecting the whole maggots treated in the step A1, washing and draining;
a3, freezing the drained whole maggots at a low temperature, and then freeze-drying until the water content is lower than 10 wt%;
a4, carrying out low-temperature ultrafine grinding on the whole maggots subjected to freeze drying to obtain the maggot dry powder.
In the step A2, the disinfection solution adopted by the soaking disinfection is a mixture of water and peroxyacetic acid disinfection stock solution, and the soaking time is 10 minutes; the volume ratio of water to peroxyacetic acid disinfection stock solution is 1: 400.
In the step A3, the low-temperature freezing temperature is-20-50 ℃, and the freezing time is 24 h.
Example 2
The embodiment provides a preparation method of a maggot wine-soaking product, which comprises the following steps:
b1, cleaning and washing the collected whole maggots to remove dirt on the surface;
b2, soaking and disinfecting the whole maggots treated in the step B1, washing and draining;
b3, putting the drained whole maggots into the wine, and sealing and storing;
and B4, taking out the whole maggots after being sealed and stored, and carrying out low-temperature ultrafine grinding to obtain the maggot feed additive.
In the step B2, the disinfection solution adopted by the soaking disinfection is a mixture of water and peroxyacetic acid disinfection stock solution, and the soaking time is 10 minutes; the volume ratio of water to peroxyacetic acid disinfection stock solution is 1: 400.
In the step B3, the weight parts of the whole maggot and the wine are as follows: 0.2: 0.8-0.4: 0.6; the sealing time is more than 2 months; the wine is pure grain wine with the alcoholic strength of 55-70 degrees.
Effect verification:
the dried maggot powder and maggot wine-soaked products prepared in examples 1 and 2 of the present invention were subjected to the effect verification of diabetes treatment and insulin level adjustment, and specific treatment verification examples are provided further below.
Verification example I, combined treatment by adopting maggot freeze-dried powder and maggot soaking wine
Shen is a Chinese medicine for treating the disease of Shanghai's institute
The treatment scheme is as follows: 1500mg of the maggot dry powder capsule prepared in example 1 is taken before meals three times a day; 2000mg of the maggot dipping wine product prepared in example 2 was taken before sleeping.
Pre-and post-OGTT comparative analysis: the interval of the secondary OGTT of the patient is 60 days, and the actual administration is 45 days. The results of the test reports of the sixth national hospital in Shanghai are shown in Table 1.
TABLE 1
Analysis from the sugar tolerance curve (fig. 1):
1. the fasting blood sugar is reduced by 0.63mmol/L, and the blood sugar is reduced from 8.0mmol/L to 5.3mmol/L in 180 minutes to return to normal.
2. The peak glucose tolerance reversed the forward shift, which was 60 minutes from the initial 120 minutes.
Insulin release profile (fig. 2) analysis:
1. the fasting insulin resistance symptoms were improved:
a: the fasting insulin release is reduced by 48.43 percent, and the blood sugar is reduced by 0.63mmol/L
B: the insulin release is reduced by 44.42% in 180 minutes, and the blood sugar returns to the standard of normal people.
It was demonstrated that insulin resistance was repaired.
2. The 60 minute insulin release and fasting fold increased from the initial 3.52 fold to 9.22 fold (5-10 fold normal), and the peak insulin release increased from the initial 5.01 fold to 11.16 fold (5-10 fold normal).
It was demonstrated that insulin sensitivity was increased.
3. The peak release of insulin is increased from 91.46 mu IU/mL to 103.2 mu IU/mL before taking the medicine, and the peak release is increased by 11.38 percent.
The above analysis proves that the insulin resistance and the insulin sensitivity of the patient are remarkably improved in two ways after the maggots are conditioned, so that the insulin level of the patient is restored to the normal level.
The results demonstrate that the patient is impaired both in insulin resistance and insulin sensitivity.
Verification example II, combined treatment by adopting maggot freeze-dried powder and maggot soaking wine
The patients: name: sex of ZhangXX Male age: 55 years old, diabetes mellitus is diagnosed for 5 years
The metformin sustained-release tablets are 0.5g and 2 granules before treatment, and all western medicines are stopped to take for 19 days.
The treatment scheme is as follows: 1500mg of the maggot dry powder capsule prepared in example 1 is taken before meals three times a day; 2000mg of the maggot dipping wine product prepared in example 2 was taken before sleeping.
Two previous and subsequent OGTT reports: the test report results of the second people hospital in Wuxi city in Jiangsu province (120 days apart) are shown in Table 2.
TABLE 2
| |
0 |
30 |
60 |
120 |
180 minutes | |
| Before taking medicine | Blood sugar value mmol/L0 | 8.41 | 13.00 | 16.72 | 17.96 | 11.87 |
| Insulin mu IU/ |
10.85 | 45.00 | 80.16 | 38.31 | 21.13 | |
| After taking the medicine | Blood sugar value mmol/L1 | 6.52 | 11.83 | 14.08 | 12.66 | 4.75 |
| Insulin mu IU/ |
6.72 | 24.18 | 35.32 | 47.81 | 10.07 |
Analysis from the sugar tolerance curve (fig. 3):
1. the fasting blood glucose is reduced from 8.41mmol/L to 6.52mmol/L and returns to normal.
2. The blood sugar is reduced from 13.00mmol/L to 11.83mmol/L in 30 minutes.
3. The blood sugar is reduced from 16.72mmol/L to 14.08mmol/L in 60 minutes.
4. The blood sugar is reduced from 17.96mmol/L to 12.66mmol/L in 120 min.
5. The blood sugar is reduced from 11.87mmol/L to 4.75mmol/L after 180 minutes and returns to normal.
6. The peak glucose tolerance reversed the forward shift from the initial 120 minutes to 60 minutes.
Analysis from insulin release curves (fig. 4):
1. fasting insulin decreased 38.06% of blood glucose and returned to normal.
2. Insulin release decreased 46.27% in 30 minutes and blood glucose decreased 1.17 mmol/L.
3. Insulin release decreased 55.94.27% over 60 minutes and blood glucose decreased 2.64 mmol/L.
4. Insulin release decreased 52.34% over 180 minutes and blood glucose decreased 5.30 mmol/L.
5. Analysis of the large drop in blood glucose by insulin from the various points of insulin release also resulted in a drop indicating significant repair of insulin resistance. This result demonstrates that the patient is impaired mainly by insulin resistance.
Verification example III, combined treatment by adopting maggot freeze-dried powder and maggot soaking wine
Patient name: Lu XX sex: male age: 36 years old 2019/3/14 treatment started and all western medicines were withheld for 71 days.
The treatment scheme is as follows: 1500mg of the maggot dry powder capsule prepared in example 1 is taken before meals three times a day; 2000mg of the maggot dipping wine product prepared in example 2 was taken before sleeping.
Two previous and subsequent OGTT reports: at 96 days intervals, HbAlc decreased from 6.7 to 5.8, and insulin levels are shown in Table 3.
TABLE 3
| |
0 |
30 |
60 |
120 |
180 minutes | |
| Before taking medicine | Insulin mu IU/ |
5.00 | 8.00 | 12.60 | 23.30 | 15.60 |
| After taking the medicine | Insulin mu IU/ |
3.43 | 10.01 | 27.74 | 26.22 | 21.97 |
Analysis from insulin release curves (fig. 5):
1. the integrated area of insulin release of the patients after taking the medicine for 96 days is greatly increased.
2. The ratio of peak insulin to fasting insulin increased from 4.66 to 8.09 and 3.43 times.
3. The peak insulin release shifted from 120 minutes onwards to 60 minutes.
4. Peak insulin increased from 23.3. mu.IU/mL to 27.74. mu.IU/mL, 19.06%.
This result demonstrates that the patient is insulin sensitive as the main lesion.
Verification example four treatment with the maggot wine-soaked product alone
Name and gender of women age 65 years old with diabetes mellitus 10 years
The treatment scheme is as follows: twice a day, 2000mg of the maggot extract product prepared in example 2 each time.
Pre-and post-OGTT comparative analysis: the secondary OGTT interval of the patients is 156 days, and the patients are actually taken for 156 days. The results are shown in Table 4.
TABLE 4
Analysis from the sugar tolerance curve (fig. 6):
1. the fasting blood sugar is reduced from 7.45mmol/L to 7.00 mmol/L.
2. The blood sugar is reduced from 15.13mmol/L to 13.54mmol/L in 60 minutes.
3. The blood sugar is reduced from 17.25mmol/L to 8.20mmol/L to return to normal after 120 minutes.
4. The sugar resistance peak value is reversed and moved forward, and is moved forward to 60 minutes from the initial 120 minutes, which accords with the sugar resistance special syndrome of normal people.
Analysis from insulin release curves (fig. 7):
1. the fasting insulin is reduced by 30.16 percent, and the blood sugar is reduced by 0.45 mmol/L.
2. Insulin release decreased 74.08% over 120 minutes and blood glucose decreased 9.05 mmol/L.
The significant elimination of insulin resistance is proved by two points above 1-2
3. The insulin release to recovery ratio increased from the initial 1.67-fold to 2.62-fold for 30 minutes.
The insulin sensitivity was also shown to be increased based on the above analysis.
2000mg of the maggot soaking wine product prepared in the example 2 is equivalent to 500mg of the maggot dry powder prepared in the example 1, and the fourth verification example shows that the dosage of the maggot soaking wine product used by a patient alone is far lower than that of the maggot soaking wine product used in the above three cases, and the effect is also obvious, so that the effect of the maggot soaking wine product used by a patient alone is actually better than that of the maggot powder.
Through the analysis of the four cases of patients on the treatment effect by the previous and subsequent OGTT determination, the maggot has the advantages of safety, long-acting effect and whole body conditioning when being used for treating the diabetes. The adjuvant and the syndrome of eliminating insulin resistance and promoting normal insulin secretion are found in the medical sense.
At present, the diabetes patient is treated by the maggot for a period of time, and the measurement of secondary OGTT before and after the patient is compared proves that the insulin resistance of the patient can be restored and the insulin sensitivity can be improved medically, the blood sugar control of the patient can be excellent after all the drug treatments are stopped (2-5 years), the glycosylated hemoglobin is less than 6.3, and no rebound exists up to now.
The invention has many applications, and the above description is only a preferred embodiment of the invention. It should be noted that the above examples are only for illustrating the present invention, and are not intended to limit the scope of the present invention. It will be apparent to those skilled in the art that various modifications can be made without departing from the principles of the invention and these modifications are to be considered within the scope of the invention.
Claims (7)
1. Use of a maggot soaking wine product in the preparation of a composition for treating diabetes;
the preparation method of the maggot wine-soaking product comprises the following steps:
b1, cleaning and washing the collected whole maggots to remove dirt on the surface;
b2, soaking and disinfecting the whole maggots treated in the step B1, washing and draining;
b3, putting the drained whole maggots into the wine, and sealing and storing;
b4, taking out the whole maggots after being sealed and stored, and carrying out low-temperature ultrafine grinding to obtain the maggot feed;
the weight parts of the whole maggot and the wine are as follows: 0.2: 0.8-0.4: 0.6.
2. Use of a maggot extract product for the preparation of a composition for regulating insulin levels; the preparation method of the maggot wine-soaking product comprises the following steps:
b1, cleaning and washing the collected whole maggots to remove dirt on the surface;
b2, soaking and disinfecting the whole maggots treated in the step B1, washing and draining;
b3, putting the drained whole maggots into the wine, and sealing and storing;
b4, taking out the whole maggots after being sealed and stored, and carrying out low-temperature ultrafine grinding to obtain the maggot feed;
the weight parts of the whole maggot and the wine are as follows: 0.2: 0.8-0.4: 0.6.
3. Use according to claim 1 or 2, wherein the composition comprises any of a pharmaceutical product, a nutraceutical product, a food product.
4. The use of claim 1 or 2, wherein the formulation of the maggot extract product comprises any one of capsules, tablets, pills, powder, compound granules, health wine, oral liquid or lyophilized powder.
5. The use of claim 1, wherein in step B2, the disinfecting liquid used for immersion disinfection is a mixture of water and peroxyacetic acid disinfectant stock solution.
6. The use according to claim 1, wherein in step B3, the sealing time is more than 2 months.
7. The use according to claim 1, wherein in step B3, the wine is pure grain wine with an alcoholic strength of 55-70 °.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910642598.7A CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
| PCT/CN2019/104318 WO2021007934A1 (en) | 2019-07-16 | 2019-09-04 | Application of liquor product with soaked lucilia sericata for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910642598.7A CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327373A CN110327373A (en) | 2019-10-15 |
| CN110327373B true CN110327373B (en) | 2021-03-16 |
Family
ID=68145485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910642598.7A Active CN110327373B (en) | 2019-07-16 | 2019-07-16 | Application of maggot wine-soaked product in treatment of diabetes |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110327373B (en) |
| WO (1) | WO2021007934A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302213A (en) | 2019-07-16 | 2019-10-08 | 华祥荣 | Maggot is for treating the application in diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335241A (en) * | 2011-10-12 | 2012-02-01 | 郭聚忠 | Medicine for treating diabetes mellitus associated with hyperlipemia, and preparation method thereof |
-
2019
- 2019-07-16 CN CN201910642598.7A patent/CN110327373B/en active Active
- 2019-09-04 WO PCT/CN2019/104318 patent/WO2021007934A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335241A (en) * | 2011-10-12 | 2012-02-01 | 郭聚忠 | Medicine for treating diabetes mellitus associated with hyperlipemia, and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 中西医结合治疗2 型糖尿病胰岛素抵抗的Meta 分析;聂春丽等;《世界中医药》;20180331;第774页右栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021007934A1 (en) | 2021-01-21 |
| CN110327373A (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110327373B (en) | Application of maggot wine-soaked product in treatment of diabetes | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN107551192A (en) | A kind of Traditional Chinese medicine compound composition with treatment CKD and preparation method and application | |
| CN104206577A (en) | Camellia nitidissima health care tea cream and processing method thereof | |
| CN103191295A (en) | Medicine for treating diabetes mellitus | |
| WO2021007933A1 (en) | Application of maggots in treatment of diabetes | |
| CN113041300B (en) | Prescription for treating diabetes and its application | |
| CN108635389A (en) | A kind of preparation method of Chinese medicine preparation and its electuary that treating diabetes B | |
| CN107737280A (en) | Chinese medicine composition for treating diabetes and its preparation method and application | |
| CN106924581A (en) | It is a kind of to treat medicinal liquor of stomachache and preparation method thereof | |
| CN103340991B (en) | Oral liquid for nursing diabetics and preparation method thereof | |
| CN105995971A (en) | Nutritional liquid food for promoting diabetes recovery and preparation method thereof | |
| CN110876717A (en) | Preparation method of product capable of stabilizing blood sugar | |
| CN105535947A (en) | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition | |
| CN102631498B (en) | Chinese medicinal composition | |
| CN111557447A (en) | Preparation of dendrobium officinale polysaccharide buccal tablet and application of dendrobium officinale polysaccharide buccal tablet in immune enhancement | |
| CN1709335A (en) | Chinese medicine for treating infantile apositia and deficiency of vital energy of spleen and stomach, and its preparing method | |
| CN111053848A (en) | Traditional Chinese medicine composition for conditioning heat accumulation constitution of children and preparation method thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN1954879A (en) | Granule of zhamusa-four-does and its preparation method | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN107007748A (en) | Improve Chinese medicine composition, medicine of physically weak symptom and its preparation method and application | |
| CN105029301A (en) | Sweet potato cake suitable for 'three-high' people and preparation method of sweet potato cake | |
| CN112168861A (en) | Astragalus granules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |